|Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D.||Co-Founder||546.08k||N/A||1955|
|Dr. Steen Meier Knudsen||Founder & Chief Scientific Officer||185.11k||N/A||1961|
|Ms. Ulla Hald Buhl||Founder, COO, Chief IR & Communications||370.22k||N/A||1964|
|Mr. Stefano R. Carchedi||CEO, Pres & Director||N/A||N/A||1962|
|Mr. Thomas Jensen||Founder & Sr. VP of Information Technologies||N/A||N/A||1978|
|Mr. Claus Frisenberg Pedersen||Chief Commercial Officer||N/A||N/A||1972|
|Mr. Jens Erik Knudsen CPA, M.B.A.||Chief Financial Officer||N/A||N/A||N/A|
|Mr. James G. Cullem||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Annie Rasmussen||Chief of Clinical Operations||N/A||N/A||1957|
|Dr. Marie Foegh||Chief Medical Officer||N/A||N/A||N/A|
Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes stenoparib, a PARP inhibitor in Phase II clinical trials for the treatment of ovarian cancer, as well as in pre-clinical studies for the treatment of coronavirus; dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor, which is in Phase II clinical for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin for the treatment of brain cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in HÃ¸rsholm, Denmark.
Allarity Therapeutics A/S’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.